Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To update the CCAFU recommendations for the management of muscle-invasive bladder cancer (MIBC).
Methods: A systematic review (Medline) of the literature from 2022 to 2024 was carried out, taking into account the elements of the diagnosis, the treatment options and the monitoring of NMIBC and MIBC, evaluating the references with their level of evidence.
Results: MIBC is diagosed after the must complete tumor resection possible . CT-Urography coupled with chest CT scans are used to assess the extent of MIBC. Multiparametric pelvic MRI may be an alternative imaging approach. Cystectomy combined with standard lymph node dissection is the standard treatment for nonmetastatic MIBC. Neoadjuvant cispaltine-based chemotherapy should be used in patients in good general health with satisfactory renal function. Enterocystoplasty is proposed for men and women in the absence of contraindications and when urethral recutting is negative on extemporaneous examination; otherwise, transileal cutaneous ureterostomy is the recommended method of urinary diversion. All patients should be included in an improved recovery after surgery (ERAS) protocol. For metastatic MIBC, first-line treatment with enfortumab vedotin and pembrolizumab is recommended. Second-line treatment with platinum-based chemotherapy is recommended.
Conclusion: Updating the ccAFU recommendations should improve patient management and enhance the diagnosis and treatment of MIBC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fjurol.2024.102741 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients.
Int J Cancer
September 2025
Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Bladder cancer (BlCa) exhibits a highly heterogeneous molecular landscape and treatment response, underlining the pressing need for personalized prognosis. N6-methyladenosine (m6A) constitutes the most abundant RNA modification, modulates RNA biology/metabolism, and maintains cellular homeostasis, with its dysregulation involved in cancer initiation and progression. Herein, we evaluated the clinical value of METTL3 m6A methyltransferase, the main catalytic component of m6A methylation machinery, in improving BlCa patients' risk stratification and prognosis.
View Article and Find Full Text PDFOncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and future directions.
Curr Opin Urol
September 2025
Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Purpose Of Review: Nonmuscle-invasive bladder cancer (NMIBC) patients with BCG-unresponsive disease have limited treatment options beyond radical cystectomy. With ongoing BCG shortages and the urgent need for bladder-preserving alternatives, this review examines the emerging role of oncolytic virus therapy as a novel intravesical treatment approach for this challenging patient population.
Recent Findings: Multiple oncolytic viral platforms have entered clinical trials for NMIBC treatment, demonstrating promising efficacy and safety profiles.
IGHA1 and IGHG1 Expression Panel Predicts Anti-PD-L1 Response in Muscle-Invasive Bladder Cancer.
Mol Carcinog
September 2025
Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
B cells located in tertiary lymphoid structures (TLSs) may undergo clonal expansion, somatic hypermutation, isotype switching, and tumor-specific antibody production, suggesting that antibody-producing plasma cells may be involved in antitumor immunity. This study used a combination of single-cell sequencing (five samples from our center, and four samples from PRJNA662018) and spatial transcriptome (one sample from our center, and four samples from GSE169379) research methods to investigate the relationship between TLSs and the immunoglobulin repertoire in muscle invasive bladder cancer (MIBC). 405 patients with MIBC from TCGA and 348 patients with metastatic urothelial carcinoma on PD-L1 inhibitor treatment from the IMvigor210 trial were included in this study.
View Article and Find Full Text PDFMetastatic cardiac tumor resulting in cardiogenic shock from muscle-invasive urothelial carcinoma of the bladder: a case report.
Urol Case Rep
September 2025
Main Line Health, Division of Urology, Wynnewood, PA, USA.
Muscle-invasive bladder cancer (MIBC) with cardiac metastasis typically carries a very poor prognosis. A Black woman in her 70s developed high-grade urothelial carcinoma with squamous differentiation invading the bladder muscle. Despite chemotherapy, radiation, and nephrostomy, the disease progressed.
View Article and Find Full Text PDFCu(OH)PO@PAA Nanoparticles for Highly Effective Combination of Chemodynamic, Photodynamic and Photothermal Therapies Against Bladder Cancer.
Int J Nanomedicine
September 2025
Department of Ultrasonic Imaging, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Background: Due to the complex structure and variable microenvironment in the progression of bladder cancer, the efficacy of traditional treatment methods such as surgery and chemotherapy is limited. Tumor residual, recurrence and metastasis are still difficult to treat. The integration of diagnosis and treatment based on nanoparticles can offer the potential for precise tumor localization and real-time therapeutic monitoring.
View Article and Find Full Text PDF